Skin appendage disorders · 2026
Financial Burden of Scarring Alopecia: Insights from the Cicatricial Alopecia Patient Assessment and Impact Report-Scarring Alopecia Foundation Survey Study on Economic and Psychosocial Impact.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spindler Archie, Maas Derek, Zappi Isabella, Brinks Anna L, Lawrence Carli Needle, Kearney Caitlin A, Pickford Jean, Jefferson Itisha S, Shobajo Morinola, Senna Maryanne M, Shapiro Jerry, Lo Sicco Kristen I
Аннотация
INTRODUCTION: Alopecia treatments can incur significant patient costs; however, this monetary impact has yet to be characterized in scarring alopecia (SA) patients. Our study aims to characterize the financial burden of SA and its psychosocial impact.
METHODS: We conducted a cross-sectional study using survey data collected by the Scarring Alopecia Foundation between December 2, 2022, and December 16, 2022. Financial burden metrics and quality of life impacts were analyzed using RStudio.
RESULTS: A total of 1,047 individuals (97.4% female, mean age 57.8 years) completed the survey. Most patients (51.4%) spent USD 1-100 monthly on medical treatments, followed by USD 101-250 (22.8%). Annual costs for nonprescription treatments were most commonly <USD 100 (37%), followed by USD 101-500 (26.5%). Annual costs for nonmedical items were more evenly distributed, yet nearly one in five patients spent >USD 1,000. No differences were seen between general dermatologist and hair loss specialist patients. Most patients felt only somewhat supported or not supported by insurance with no difference between public and private coverage. Additionally, no financial metrics were significantly associated with differences in quality of life.
CONCLUSION: Regardless of provider type, patients with SA face substantial out-of-pocket costs for nonmedical items with limited insurance support. Further advocacy is needed to lessen the financial burden faced by SA patients.
METHODS: We conducted a cross-sectional study using survey data collected by the Scarring Alopecia Foundation between December 2, 2022, and December 16, 2022. Financial burden metrics and quality of life impacts were analyzed using RStudio.
RESULTS: A total of 1,047 individuals (97.4% female, mean age 57.8 years) completed the survey. Most patients (51.4%) spent USD 1-100 monthly on medical treatments, followed by USD 101-250 (22.8%). Annual costs for nonprescription treatments were most commonly <USD 100 (37%), followed by USD 101-500 (26.5%). Annual costs for nonmedical items were more evenly distributed, yet nearly one in five patients spent >USD 1,000. No differences were seen between general dermatologist and hair loss specialist patients. Most patients felt only somewhat supported or not supported by insurance with no difference between public and private coverage. Additionally, no financial metrics were significantly associated with differences in quality of life.
CONCLUSION: Regardless of provider type, patients with SA face substantial out-of-pocket costs for nonmedical items with limited insurance support. Further advocacy is needed to lessen the financial burden faced by SA patients.